

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Shu-Ping Yang et al.	Examiner:	Maury A. Audet
Serial No.:	10/601,059	Group Art Unit:	1654
Filed:	June 20, 2003	Docket:	1443.064US1
Title:	ANTI-CHONDROSARCOMA COMPOUNDS		

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I, Robin A. Chadwick, am the attorney of record for the above identified patent application as evidenced by the Power of Attorney filed in the present application on June 20, 2003. I am making this petition on behalf of Kimberly-Clark Worldwide, Inc., the assignee of the present invention. As the attorney of record, I am empowered to act on behalf of the assignee and, in accordance with 37 C.F.R. § 1.321(b)(iv), to sign this terminal disclaimer.

Certificate Under 37 C.F.R. § 3.73(b)

Your petitioner, Kimberly-Clark Worldwide, certifies that it is the owner of the entire right, title and interest in and to the above-identified patent application (Serial No. 10/601,059) and to U.S. Serial No.10/219,329 (now U.S. Patent No. 7,071,164). Your petitioner owns the entire right, title, and interest of these applications by nature of the assignments executed and filed for both of these applications, as follows:

The assignment for U.S. Serial No.10/219,329 was recorded with the United States Patent and Trademark Office on August 15, 2002 at Reel 013199, Frame 0272.

The above-identified patent application (Serial No. 10/601,059) was recorded with the United States Patent and Trademark Office on December 15, 2003 at Reel 014786, Frame 0417.

The undersigned representative of the assignee has reviewed the evidentiary documents of title and certifies that to the best of assignee's knowledge and belief, title is in the assignee, Kimberly-Clark Worldwide, Inc., seeking to take the action set forth in this disclaimer.

Terminal Disclaimer

Your petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified patent application, which would extend beyond the expiration date of the full statutory term, as presently shortened by any terminal disclaimers, of U.S. Patent No. 7,071,164. Petitioner hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to U.S. Patent No. 7,071,164 and the legal title of the above-identified application and any patent granted thereon remain common, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

Limitations on the Disclaimer

Your petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent No. 7,071,164 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration date of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title as stated hereinabove.

TERMINAL DISCLAIMER

Serial Number: 10/601,059

Filing Date: June 20, 2003

Title: ANTI-CHONDROSARCOMA COMPOUNDS

Page 3

Dkt: 1443.064US1

Fee Status

Please charge Deposit Account 19-0743 in the amount of \$130.00, which is required under 37 C.F.R. § 1.20(d) to file a statutory disclaimer. The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0743.


Respectfully submitted,

SHU-PING YANG ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER &
KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(516) 795-6820

Date August 8, 2006

By 

Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8TH day of August 2006.

CANDIS BUENDING

Name


Signature